about
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukem...
Read More
5.05
0.00
(0.00%)
520.6K
XNAS Volume
XNAS 30 Jul, 2025 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bullish
MEI Pharma Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..